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Abstract: Men who have sex with men (MSM) may be at higher risk for human papillomavirus
(HPV)-associated cancers. Healthcare professionals’ recommendations can affect HPV vaccination
uptake. Since 2016, MSM up to 45 years have been offered HPV vaccination at genitourinary medicine
(GUM) clinics in a pilot programme, and primary care was recommended as a setting for opportunistic
vaccination. Vaccination prior to potential exposure to the virus (i.e., sexual debut) is likely to be
most efficacious, therefore a focus on young MSM (YMSM) is important. This study aimed to explore
and compare the knowledge and attitudes of UK General Practitioners (GPs) and sexual healthcare
professionals (SHCPs) regarding HPV vaccination for YMSM (age 16–24). A cross-sectional study
using an online questionnaire examined 38 GPs and 49 SHCPs, including 59 (67.82%) females with
a mean age of 40.71 years. Twenty-two participants (20 SHCPs, p < 0.001) had vaccinated a YMSM
patient against HPV. GPs lack of time (25/38, 65.79%) and SHCP staff availability (27/49, 55.10%) were
the main reported factors preventing YMSM HPV vaccination. GPs were less likely than SHCPs to
believe there was sufficient evidence for vaccinating YMSM (OR = 0.02, 95% CI = 0.01, 0.47); less likely
to have skills to identify YMSM who may benefit from vaccination (OR = 0.03, 95% CI = 0.01, 0.15);
and less confident recommending YMSM vaccination (OR = 0.01, 95% CI = 0.00, 0.01). GPs appear to
have different knowledge, attitudes, and skills regarding YMSM HPV vaccination when compared
to SHCPs.
Keywords: vaccine uptake; vaccine communication; sexual minorities; papillomaviruses
1. Introduction
Human papillomavirus (HPV) vaccination of young men who have sex with men (YMSM)
(age 16–24) potentially has important implications for cancer prevention worldwide. HPV is one of the
most common sexually transmitted infections [1]. Over 70% of MSM are carriers of HPV [2,3]. HPV
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infection is associated with other anogenital and oropharyngeal cancers [4]. Anal cancer incidence has
increased rapidly in recent years [5], with approximately 95% of anal cancers caused by HPV [6]. MSM
(men who have sex with men) carry a disproportionate burden of anal cancer (15:1 compared with
heterosexual men) [7]. Relative to human immunodeficiency virus (HIV)-negative men or women,
HIV-negative MSM have a 4-fold higher risk of developing anal cancer, and HIV-positive MSM have
up to an 80-fold higher risk [8]. Approximately 72% of oropharyngeal cancer cases in the United States
from 2008–2012 was attributable to HPV, with an annual incidence rate of 7.6 per 100,000 population [9].
Prevention of HPV-related disease is a key public health issue. The United Kingdom’s (UK)
current strategy is to offer publicly funded vaccination only to girls aged 12–14 (prior to the legal
age of consent at 16 years), which is intended to protect males through herd immunity. This decision
was made on the basis of cost effectiveness [10], although more recent studies have called this into
question [11]. This benefit does not extend to MSM. Public Health England estimates that 3.2% of
the UK population are lesbian, gay, or bisexual [12], which suggests that almost one million UK men
may not protected from HPV-associated anogenital warts and cancers. In November 2015, the Joint
Committee on Vaccination and Immunisation (JCVI) recommended the HPV vaccination programme
be extended to MSM aged up to 45 years via genitourinary medicine (GUM) clinics, HIV clinics,
or opportunistically through general practice clinics (GPs) [13].
Vaccination is likely to be most efficacious before exposure to HPV [14], however the majority
of men do not identify as gay or bisexual before they engage in sexual contact with other men [15],
and many men do not disclose their sexual identity and/or behaviour to their physician. In attempts
to address this issue, UK healthcare professionals (HCP) have recently been issued guidance from
NHS England recommending that they enquire about a patient’s sexual orientation at “every face to
face contact with the patient, where no record of this data already exists” [16]. Such policies have the
potential to exacerbate stigmatisation of LGBTQ patients accessing healthcare services if they feel they
will be asked to disclose their sexual orientation every time they access a service, whether it is relevant
to their presenting complaint or not [17]. Best practice guidance for discussing sexual behaviour has
been produced from UK charities, such as Stonewall [18].
It is crucial to engage widely with HCPs expected to vaccinate YMSM against HPV. Patients and
parents of younger children place a strong emphasis on the recommendations (or otherwise) of a
HCP in decision-making regarding vaccinations [19–21]. GPs will arguably have more opportunity
to vaccinate men before sexual debut compared to GUM clinics, given that men are more likely to
attend a GUM clinic after the first sexual encounter [15]. It is also important to identify appropriate
strategies to support any new HPV vaccination programmes in the future and highlight any barriers
and facilitators to the programmes’ effective implementation.
In a survey of 131 sexual healthcare professionals (SHCPs), 95% of clinicians supported a targeted
HPV vaccination programme in MSM within GUM services but expressed concern that alone this
strategy was too late and too limited for most MSM [22]. This study was specific to clinicians with
expertise in sexual health, and did not include other HCPs who may be involved in vaccination, such as
GPs. It was also conducted prior to the recent JCVI recommendation. The aim of this study is to
understand and compare the knowledge, perceptions, and attitudes of UK GPs and SHCPs regarding
HPV vaccination for YMSM.
2. Materials and Methods
An exploratory cross-sectional survey of GPs and SHCPs was conducted as part of a
mixed-methods study. SCHPs included GUM consultants, doctors-in-training, and nurses working
in sexual health clinics. Between September 2016 and January 2017, convenience sampling was
used to recruit participants through an email invitation distributed by the Royal College of General
Practitioners (RCGP), British HIV Association (BHIVA), British Association for Sexual Health and HIV
(BASHH), Society of Sexual Health Advisors (SSHV), Society for the Study of Sexually Transmitted
Diseases in Ireland (SSSTDI), and the University of Bristol Centre for Academic Primary Care (CAPC).
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The email invitation included a link to the online survey and a participant information sheet which
explained that participation implied consent. At the end of the anonymous survey, GPs were invited to
provide contact details if they wished to take part in a follow-up interview (findings not yet published).
Similar to Nadarzynski et al. [23], participants were asked to distribute the e-survey to co-workers to
increase the number of responses using snowballing techniques.
The questionnaire aimed to capture knowledge and attitudes towards HPV vaccination for
YMSM, as well as any barriers or facilitators. YMSM were chosen as the focus for this study as greater
understanding of factors affecting HPV vaccination in this age group could improve the efficacy
of HPV vaccination programmes for MSM by targeting younger men before they engage in sexual
activity. Questionnaire content was informed by a study steering group comprising two lesbian,
gay, bisexual, transgender and queer (LGBTQ) group stakeholders and three MSM sexual health
researchers from England and Northern Ireland, and piloted with HCPs prior to wider distribution.
The questionnaire was adapted from a HCP HPV attitude scale developed by Nadarzynski et al. [23],
and a HCP pre-exposure prophylaxis (PrEP) knowledge and attitude scale [24]. Question items focused
on the barriers and facilitators to vaccinating YMSM provided pre-specified options based on existing
literature, with an option for free text responses. Individual questionnaire items used either binary
(“yes” or “no”) or ordinal (“high”, “medium”, “low”) response measures for knowledge questions.
Basic demographic information, including participant age, gender, clinical role, and years of experience
were gathered.
Descriptive statistics summarised demographic, attitude, and knowledge data. Fisher’s exact
testing and unpaired t-tests were utilised for comparison of demographics. Due to null responses
for some categories, sexual orientation was converted to a binary variable (“heterosexual or straight”
vs. “gay, lesbian, or bisexual”) for the analysis. Ordinal knowledge variables were converted to binary
responses (“high/medium” vs. “low/none”). Attitudinal responses were converted into positive
(“yes”) or negative (“unsure” or “no”) binary variables. Simple and multiple logistic regression
techniques were utilised to compare the responses of GPs and SHCPs to the knowledge and attitude
questions. Adjusted analysis controlled for the effects of participant age, gender, sexual orientation,
and years of experience. Hosmer–Lemeshow goodness of fit testing was performed to assess accuracy
of multiple logistic regression models. All analysis was conducted using Stata version 14 (StataCorp.
2015. Stata Statistical Software: Release 14. College Station, TX, USA: StataCorp LP.).
Ethical Approval
This study received ethical approval from the Queens University (Belfast) School of Nursing and
Midwifery Research Ethics Committee (ref. 39.GPrue.05.16.M8.V2).
3. Results
In total, 87 participants completed the survey. Demographic data was incomplete for three SHCPs,
but overall individual question response rates were high (range: 94.25–100%). Thirty-eight GPs and
49 SHCPs (35 GUM specialists, 8 specialist nurses, 3 hospital sexual health specialists, and 3 other)
completed the questionnaire. Participants included 59 females (67.82%), with a mean age of 40.71 years,
and a median 14 years of experience (IQR (Interquartile Range) 8, 24). There were no significant
differences between GPs and SHCPs. Further demographics are shown in Table 1.
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Table 1. Survey participant demographics.
Demographics GPs (n = 38) SHCPs (n = 49) p
Age (mean years, SD) 39.84 (9.02) 41.02 (10.72) 0.59
Female gender (n, %) 26 (68.42%) 33 (67.35%) 0.46
Sexual orientation (n, %)
Heterosexual or straight 37 (97.37%) 38 (77.55%)
0.06
Gay or lesbian 1 (2.63%) 9 (18.37%)
Bisexual 0 1 (2.04%)
Prefer not to say 0 1 (2.04%)
Years of experience (mean, SD) 15.13 (9.10) 16.84 (11.56) 0.46
GPs: General Practitioners; SHCPs: sexual healthcare professionals.
SHCPS were more likely than GPs to have vaccinated a YMSM patient against HPV (20/49
(47.83%) vs. 2/38 (5.6%), p < 0.001), more likely to be aware of the recent JCVI recommendations
(adjusted OR = 0.03, 95% CI = 0.01, 0.11), and more likely to report they knew enough to have an
informed discussion with MSM about HPV vaccination (adjusted OR = 0.04, 95% CI = 0.01, 0.14). Thirty
GPs (78.95%) stated they have a “low level of knowledge” or “no knowledge” of HPV vaccination
for YMSM, compared to 6 (12.24%) SHCPs (adjusted OR = 0.02, 95% CI = 0.00, 0.10), but there were
no significant differences in knowledge ratings regarding overall HPV knowledge or HPV in females
(see Table 2).
GPs attitudes towards HPV vaccination in YMSM differed from SHCPs (see Table 3). GPs were less
likely to agree that HPV vaccination should be widely available for both genders (adjusted OR = 0.30,
95% CI = 0.09, 0.98) or MSM (adjusted OR = 0.30, 95% CI = 0.09, 0.98) based on current evidence.
Even if a gender-neutral programme existed in the UK, GPs were less likely to recommend HPV
vaccination to MSM (adjusted OR = 0.33, 95% CI = 0.13, 0.88) and they were less likely to believe the
majority of YMSM would be willing to receive the vaccine (adjusted OR = 0.13, 95% CI = 0.04, 0.41).
Paradoxically, there was no significant difference in the numbers of GPs who would recommend the
HPV vaccination to their own son (33/38, 86.84%) compared to SHCPs (49/49, 100%, p = 0.36).
When asked about whether they ask patients about sexual orientation “if it is relevant to the
consultation”, there was no difference between the responses of GPs (31/38, 81.58%) and SHCPs
(40/46, 86.96%, p = 0.57). GPs were much less likely to believe that a young person would disclose
their sexual orientation to them (adjusted OR = 0.17, 95% CI = 0.06, 0.50), less confident that they
had the skills to identify YMSM who may benefit from HPV vaccination (adjusted OR = 0.03, 95%
CI = 0.01, 0.15), and they reported lower levels of confidence in recommending HPV vaccination for
YMSM (adjusted OR = 0.04, 95% CI = 0.01, 0.18).
GPs and SCHPs reported different factors that would most affect their ability to deliver HPV
vaccination for young MSM (see Table 4). GPs highlighted “no time” as a key limiting factor (25/38,
65.79%), while SCHPs felt “staff availability” (27/49, 55.10%) was the most important limitation.
The majority of GPs (28/38, 73.68%) felt that additional training was needed to support HPV
vaccination for MSM in primary care, while SHCPs felt computer prompts would be most useful
(18/35, 51.43%) (see Table 5).
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Table 2. GPs and SHCPs knowledge regarding HPV vaccination.
Statement GPs (n = 38) SHCPs (n = 49) Unadj OR 95% CI Adj OR 95% CI
n (%) High/Medium Low/None High/Medium Low/None
How would you rate your knowledge of HPV? * 34 (89.47%) 4 (10.53%) 47 (95.92%) 1 (2.04%) 0.19 0.02, 1.81 0.22 0.02, 2.44
How would you rate your knowledge of HPV vaccination
for females? ** 37 (97.39%) 1 (2.63%) 46 (93.88%) 1 (2.04%) 0.86 0.52, 14.24 1.77 0.05, 64.14
How would you rate your knowledge of HPV vaccination
for MSM? *** 7 (18.42%) 30 (78.95%) 42 (85.71%) 6 (12.24%) 0.04 0.01, 0.12 0.02 0.00, 0.10
Yes No Yes No
Are you aware of the recent JCVI recommendation for HPV
and MSM? 6 (15.79%) 32 (84.21%) 41 (83.67%) 8 (16.33%) 0.04 0.01, 0.13 0.03 0.01, 0.11
Do you know enough about HPV and HPV vaccination to
have an informed discussion with MSM patients? 10 (26.32%) 28 (73.68%) 44 (89.80%) 5 (10.20%) 0.04 0.01, 0.14 0.04 0.01, 0.14
* Missing responses from one SHCP; ** Missing responses from two SHCPs; *** Missing responses from one GP and one SHCP. Note—Hosmer-Lemeshow testing for goodness-of-fit
p > 0.05; HPV: human papillomavirus; JCVI: Joint Committee on Vaccination and Immunisation; MSM: Men who have sex with me; Unadj OR: unadjusted odds ratios; Adj OR: adjusted
odds ratios.
Table 3. GPs and SHCPs attitudes towards HPV vaccination for YMSM.
Statement GPs (n = 38) SHCPs (n = 49)
Unadj OR 95% CI Adj OR 95% CI
n (%) Yes No/Unsure Yes No/Unsure
HPV vaccination should be widely available for both
sexes based on current evidence. 25 (65.79%) 13 (34.21%) 43 (87.76%) 6 (12.24%) 0.29 0.10, 0.86 0.30 0.09, 0.98
HPV vaccination should be widely available to MSM
based on current evidence. ˆ 27 (71.05%) 11 (28.95%) 48 (97.96%) 1 (2.04%) 0.05 0.01, 0.45 0.30 0.09, 0.98
If there was a gender neutral HPV vaccination
programme in the UK, would you still recommend
targeted HPV vaccination?
16 (42.11%) 22 (57.89%) 34 (69.39%) 15 (30.61%) 0.32 0.13, 0.78 0.33 0.13, 0.88
Targeted HPV vaccination should be based on
individual assessment of each MSM. 16 (42.11%) 22 (57.89%) 15 (30.61%) 34 (69.39%) 1.74 0.71, 4.30 1.91 0.70, 5.19
HPV causes too few cancers among MSM to make it
worthwhile to offer vaccination. * 1 (2.63%) 36 (94.74%) 0 49 (100%) N/A N/A
HPV causes too few cancer among HIV-positive
MSM to make it worthwhile to offer vaccination. ** 1 (2.63%) 36 (94.74%) 0 48 (97.83%) N/A N/A
The majority of MSM would be willing to receive the
HPV vaccine. 16 (42.11%) 22 (57.89%) 41 (83.67%) 8 (16.33%) 0.16 0.06, 0.44 0.13 0.04, 0.41
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Table 3. Cont.
Statement GPs (n = 38) SHCPs (n = 49)
Unadj OR 95% CI Adj OR 95% CI
n (%) Yes No/Unsure Yes No/Unsure
The majority of young MSM (<24 years) would be
willing to receive the HPV vaccine. 21 (55.26%) 17 (44.74%) 41 (83.67%) 8 (16.33%) 0.28 0.10, 0.75 0.14 0.04, 0.49
HPV vaccination would encourage MSM to engage
with sexual health services. 17 (44.74%) 21 (55.26%) 33 (67.35%) 16 (32.65) 0.45 0.19, 1.10 0.42 0.16, 1.11
Vaccinating MSM could increase the likelihood of
unsafe sex. 3 (7.89%) 35 (92.11%) 1 (2.17%) 48 (97.83%) 3.97 0.40, 39.86 3.34 0.32, 35.02
I have the skills to identify MSM that would benefit
from the HPV vaccine. 3 (7.89%) 35 (92.11%) 34 (69.39%) 15 (30.61%) 0.04 0.01, 0.16 0.03 0.01, 0.15
I am confident in recommending HPV vaccination for
young MSM (<24 years). 12 (31.58%) 26 (68.42%) 43 (87.76%) 6 (12.24%) 0.06 0.02, 0.19 0.04 0.01, 0.18
I am confident that a young person would disclose
their sexual orientation to me. 15 (39.47%) 23 (60.53%) 38 (77.55%) 11 (22.45%) 0.21 0.08, 0.55 0.17 0.06, 0.50
Unadj OR: unadjusted odds ratios; Adj OR: adjusted odds ratios; * Missing responses from one SHCP; ** Missing responses from one SHCP and one GP; N/A: unable to calculate OR.
ˆ Hosmer: Lemeshow goodness-of-fit test p < 0.05.
Int. J. Environ. Res. Public Health 2018, 15, 151 7 of 10
Table 4. Most frequently ranked factors preventing GPs and SHCPs vaccinating YMSM against HPV.
Factor GPs Agree (n, %) Rank SHCPs Agree (n, %) Rank
Lack of time in consultation 25 (65.79%) 1 12 (24.49%) 3
Do not see MSM frequently 20 (52.63%) 2 3 (6.12%) 5
Limited access to vaccine 14 (36.84%) 3 16 (32.65%) 2
Limited availability of vaccine 9 (23.68%) 5 34 (69.39%) 1
Table 5. Most frequently ranked factors supporting GPs and SHCPs vaccinating YMSM against HPV.
Factor GPs Agree (n, %) Rank SHCPs Agree (n, %) Rank
More time in consultation 30 (78.95%) 1 21 (42.86%) 1
Training about HPV vaccine 24 (63.16%) 2 14 (28.57%) 2
Computer prompts 21 (55.26%) 3 21 (42.86%) 1
4. Discussion
This is the first UK-based study to examine the knowledge, perceptions, and attitudes of GPs and
SHCPs since the JCVI updated its recommendations to include offering HPV vaccination for MSM for
men under 45 years opportunistically in GUM and primary care. The survey findings suggest that
compared to SHCPs, GPs were less aware of the evidence for HPV vaccination for MSM, and reported
less confidence in recommending HPV vaccination to YMSM. GPs felt that lack of time and training
were the main barriers to HPV vaccination for YMSM, whereas SHCPs had greater concerns about
vaccine availability.
A similar survey targeting SHCPs was conducted prior to the JCVI recommendation of a targeted
vaccination programme for MSM [23]. SHCP attitudes around perceived value, health behaviours, and
capabilities are consistent across the two studies, and there are no clear changes following the JCVI
recommendation. This is probably not surprising given their clinical interest in preventing the spread
of HPV and exposure to MSM with sexual health problems in clinical practice. Interestingly, 74% of
respondents in that study “agreed” or “strongly agreed” that “HPV vaccination should be offered to
MSM in alternative settings such as GP practices or pharmacies” [23]. Disparities in knowledge and
attitudes towards HPV vaccination for YMSM between SHCPs and GPs, as suggested in this study’s
findings, may lead to differences in treatment and HPV prevention depending on where YMSM seek
sexual health advice. Our findings indicate GPs may have a low level of knowledge regarding HPV
vaccination among young MSM, and implementing a targeted HPV vaccination programme for YMSM
prior to exposure to HPV to maximise the cancer prevention potential that involved GPs would need
investment in clinician education, training, and support.
Studies in the United States of America explored reasons behind the low uptake of HPV
vaccination for adolescent boys, where access varies on a state by state basis. In a national survey,
Gilkey et al. found that paediatricians and family physicians delivered their recommendations
for HPV vaccination in children inconsistently, sometimes not in a timely manner or with strong
endorsement [19,25]. Alexander et al. also found variation in physicians’ recommendations of the
HPV vaccine to young males, citing the “newness” and sexual nature of the vaccine as barriers [26].
The study authors suggest American family physicians do not feel they have the time or knowledge to
counsel YMSM about the vaccine, and they do not believe they see them frequently. These findings are
consistent with our results, providing further evidence of the need for extra support and training for
GPs to help them identify YMSM and raise their awareness about the potential health benefits of HPV
vaccination in this high-risk group.
This study utilised an adapted version of a validated survey instrument that has been delivered to
SHCPs previously. There was minimal missing questionnaire data. Obtaining and comparing GP and
SHCP knowledge, perceptions, and attitudes towards HPV vaccination for MSM (including young
MSM) has proved insightful, given the JCVI recommendations that both settings could be used to
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deliver the vaccine. The lower levels of confidence and knowledge among GPs may help to explain
the low uptake of HPV vaccination for MSM in the current pilot programme to date [27].
There are a number of limitations that be considered in the interpretation of this study’s
findings. The cross-sectional design, convenience sampling approach, and exploratory nature of
the study—using pre-determined survey statements—limits the ability to draw sound inferences about
the reasons behind participant responses. The sample size is small, and while a response rate cannot be
accurately calculated it is presumably quite poor considering the RCGP has over 50,000 members and
BASHH has over 1000 members (some of whom are not based in the UK). There were no incentives
offered for participation; a practice which is known to raise study participation rates in similar studies.
Interviews with GPs who participated in this survey will provide more in-depth insight into their
views and opinions regarding HPV vaccination for YMSM.
5. Conclusions
GPs can potentially play a crucial role in the prevention of HPV-related diseases in YMSM. In order
to implement the JCVI recommendation regarding HPV vaccination for MSM most effectively, YMSM
should be identified early and offered the HPV vaccine with clear information. However, barriers to
such implementation in primary care appear to still remain. If the findings of this exploratory work
were confirmed in future research, interventions could be developed to raise awareness and educate
GPs about the benefits of HPV vaccination for MSM, and to improve the skills of GPs in sensitively
eliciting a patient’s sexual orientation to benefit the consultation and the patient–doctor relationship.
There are also other potential settings for delivering HPV vaccination to YMSM to improve access,
such as pharmacies and schools, which have not yet been explored.
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